期刊文献+

肺部给药系统及其治疗肺部疾病的进展 被引量:26

Pulmonary drug delivery systems and progress in their applications to lung disease treatment
下载PDF
导出
摘要 肺部给药系统具有肺局部药物浓度高、无首过效应、药物吸收快等优势,已成为肺部疾病治疗和促进大分子药物吸收的重要手段。本文结合肺的生理特点,着重介绍肺吸入给药的剂型、制备方法、质量评价和体内实验方法,以及肺部给药系统在肺部疾病,包括急性肺损伤、肺部感染、肺纤维化、哮喘、慢性阻塞性肺病和肺癌等治疗中的应用。 Pulmonary drug delivery systems (PDDS) have some advantages, including high drug accumulation in the lungs, no first pass effect, and rapid absorption of drugs. They have become a key way to treat lung diseases and improve the absorption of biomacromolecules. In this review, we analyze lung′s physiological features, and discuss the main dosage forms of lung inhalations, their preparation methods, the evaluation methods, and the in vivo experimental methods. The applications of pulmonary drug delivery to lung diseases, including acute lung injury, pulmonary infection, pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, and lung cancer, are also discussed.
作者 金义光 李淼
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2015年第3期289-295,322,共8页 Journal of International Pharmaceutical Research
关键词 肺部给药 急性肺损伤 肺感染 肺纤维化 肺癌 pulmonary drug delivery acute lung injury pulmonary infection pulmonary fibrosis lung cancer
  • 相关文献

参考文献45

  • 1Kwok PCL, Chan HK. Delivery of inhalation drugs to children for asthma and other respiratory diseases[J ]. A dv Drug Delivery Rev, 2014, 73: 83-88.
  • 2Frmnpton MW, Stewart JC, Oberdorster G. Inhalation of ultrafine particles alters blood leukocyte expression of adhesion molecules in humans [J]. Environ Health Perspect, 2006, 114 (I): 51-58.
  • 3Newhouse M, Hirst P, Duddu S, et all. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers [J]. Chest, 2003, 124(1): 360-366.
  • 4Asmus M. In vitro performance of two common valved holding chambers with a chlorofluorocarbon-free beclomethasone metered-dose inhaler [J]. Pharmootherapy, 2003, 23(12): 1538-1544.
  • 5Abbas A, Srour M, Tang P, et o1. Sonocrystallisation of sodium chloride particles for inhalation [J]. Chem Eng Sci, 2007, 62 (9): 2445-2453.
  • 6Chiou H, Li L, Hu T, et al. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation [J]. Int JPharm, 2007, 331(1): 93-98.
  • 7Atkins P J. Dry powder inhalers: an overview [J]]. Respir Care, 2005, 50(10): 1304-1312.
  • 8Yang W, Peters JI, O. Williams R. Inhaled nanoparticles-A carrent review[J], lnt JPharm, 2008, 356(1/2): 239-247.
  • 9Zhang J, Wu L, Chan HK, et al. Formation, characterization, and fate of in haled drug nanoparticles [J]. Adv Delivery Rev, 2011, 63: 441-455.
  • 10Adi H, Traini D, Chatx HK, et al. The influence of drug mor- phology on aerosolisation efficiency of dry powder inhaler for- mulations[J]. JPharm Sci, 2008, 97(7): 2780-2788.

二级参考文献68

共引文献58

同被引文献267

引证文献26

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部